Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PTC844 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PTC844 Low Dose | EXPERIMENTAL | Participants will receive PTC844 at a low dose once daily (QD) orally for 12 weeks. |
| PTC844 High Dose | EXPERIMENTAL | Participants will receive PTC844 at a high dose QD orally for 12 weeks. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo matching to PTC844 QD orally for 12 weeks. |
| Name | Type | Description |
|---|---|---|
| PTC844 | DRUG | PTC844 will be administered per schedule specified in the arm description. |
| Placebo | DRUG | Placebo matching to PTC844 will be administered per schedule specified in the arm description. |
Key Inclusion Criteria: * Historical diagnosis of RA as per the American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) diagnostic criteria. * Active RA disease with a threshold of moderate activity or higher as confirmed via DAS28-CRP (score of ≥3.2) at sc...
Top 20 of 28 competitors
PTC844 is an investigational small molecule being developed for the treatment of rheumatoid arthritis. It is currently in Phase 2 clinical development for this indication. The drug is being studied in participants with active rheumatoid arthritis, as part of a randomized, double-blind, placebo-controlled trial.
PTC844 is being developed by PTC Therapeutics, Inc., a biopharmaceutical company. The company is listed on the stock exchange under the ticker symbol PTCT. PTC Therapeutics is conducting clinical trials to evaluate the safety and efficacy of PTC844 in patients with rheumatoid arthritis.
PTC844 is currently in Phase 2 clinical development. It is being evaluated in a Phase 2 study for the treatment of rheumatoid arthritis. The drug is investigational and has not yet been approved by regulatory authorities. The ongoing trial is designed to assess its effects in participants with active disease.
PTC844 is being studied in a Phase 2 clinical trial with the identifier NCT07779616. This trial is titled 'Study of PTC844 in Participants With Active Rheumatoid Arthritis' and is expected to enroll 75 participants. The study is randomized, double-blind, and placebo-controlled, and is currently not yet recruiting.
PTC844 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for rheumatoid arthritis. The drug is being studied in a clinical trial to evaluate its safety and efficacy, but it has not yet received regulatory approval for any use.
PTC844 is a small molecule, not a biologic. It is being developed as an oral or injectable therapeutic for rheumatoid arthritis. The drug is currently in Phase 2 clinical trials, where it is being tested in a placebo-controlled study to determine its potential as a treatment for this condition.